Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte–macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
- 27 October 1998
- journal article
- clinical trial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 95 (22) , 13141-13146
- https://doi.org/10.1073/pnas.95.22.13141
Abstract
We conducted a Phase I clinical trial investigating the biologic activity of vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte–macrophage colony-stimulating factor in patients with metastatic melanoma. Immunization sites were intensely infiltrated with T lymphocytes, dendritic cells, macrophages, and eosinophils in all 21 evaluable patients. Although metastatic lesions resected before vaccination were minimally infiltrated with cells of the immune system in all patients, metastatic lesions resected after vaccination were densely infiltrated with T lymphocytes and plasma cells and showed extensive tumor destruction (at least 80%), fibrosis, and edema in 11 of 16 patients examined. Antimelanoma cytotoxic T cell and antibody responses were associated with tumor destruction. These results demonstrate that vaccination with irradiated autologous melanoma cells engineered to secrete granulocyte–macrophage colony-stimulating factor stimulates potent antitumor immunity in humans with metastatic melanoma.Keywords
This publication has 37 references indexed in Scilit:
- A Phase I Study of Vaccination with Autologous, Irradiated Melanoma Cells Engineered to Secrete Human Granulocyte-Macrophage Colony Stimulating Factor. Dana-Farber Cancer Institute, Boston, MassachusettsHuman Gene Therapy, 1997
- Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3International Journal of Cancer, 1995
- Interleukin-10Annual Review of Immunology, 1993
- Autologous Melanoma Vaccine Induces Inflammatory Responses in Melanoma Metastases: Relevance to Immunologic Regression and Immunothererapy.Journal of Investigative Dermatology, 1993
- Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.Journal of Clinical Investigation, 1993
- Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma VaccineAnnals of Surgery, 1992
- CYTOKINES: COORDINATORS OF IMMUNE AND INFLAMMATORY RESPONSESAnnual Review of Biochemistry, 1990
- Model Predicting Survival in Stage I Melanoma Based on Tumor ProgressionJNCI Journal of the National Cancer Institute, 1989
- Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patientsJournal of Surgical Oncology, 1988
- Dermal hypersensitivity to schistosome cercariae in rhesus monkeys during immunization and challengeJournal of Allergy and Clinical Immunology, 1974